ATHX 105

Drug Profile

ATHX 105

Alternative Names: ATHX-105

Latest Information Update: 17 Aug 2011

Price : $50

At a glance

  • Originator Athersys
  • Class Obesity therapies; Small molecules
  • Mechanism of Action Serotonin 2C receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 07 May 2009 Suspended - Phase-I for Obesity in United Kingdom (PO)
  • 23 Sep 2008 Athersys provides update on ATHX 105 development plans
  • 23 Sep 2008 Safety and pharmacokinetics data from a phase I study of a modified release formulation of ATHX 105 released by Athersys
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top